9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.47% | 18.85% | 32.35% | 40.21% | -2.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.70% | 34.42% | 50.51% | 62.35% | 70.88% |
| Operating Income | -16.70% | -34.42% | -50.51% | -62.35% | -70.88% |
| Income Before Tax | -8.39% | -19.00% | -28.60% | -68.93% | 32.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.39% | -19.00% | -28.60% | -68.93% | 32.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.39% | -19.00% | -28.60% | -68.93% | 32.57% |
| EBIT | -16.70% | -34.42% | -50.51% | -62.35% | -70.88% |
| EBITDA | -16.71% | -34.42% | -50.51% | -62.39% | -70.96% |
| EPS Basic | -5.07% | -13.19% | -12.11% | -19.44% | 75.48% |
| Normalized Basic EPS | -19.55% | -32.31% | -29.17% | -4.87% | 44.37% |
| EPS Diluted | -4.97% | -13.14% | -12.23% | -19.55% | 75.45% |
| Normalized Diluted EPS | -19.55% | -32.31% | -29.17% | -4.87% | 44.37% |
| Average Basic Shares Outstanding | 3.05% | 6.63% | 17.98% | 34.77% | 72.09% |
| Average Diluted Shares Outstanding | 3.05% | 6.63% | 17.98% | 34.77% | 72.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
